In the published article, there was an error in Table 1 as published. In the row “Any AE” under the columns “Non-biologic” and “Non-biologic Placebo,” the numbers entered of 57.10 (54.66 – 59.52) and 49.78 (47.12 – 52.44), respectively, are an accidental transposition of these same numbers from the “Intervention Pooled” and “Placebo Pooled” columns. Instead, the numbers under row “Any AE” for column “Non-biologic” should be 63.02 (56.80 – 69.03) and for column “Non-biologic Placebo” should be 48.75 (41.02 – 56.51). The corrected Table 1 appears below.
Table 1
| Proportion % (95% CI) | Risk difference % (95% CI) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Intervention pooled | Placebo pooled | Biologic | Biologic placebo | Non-biologic | Non-biologic placebo | Biologic | Non-biologic | Pooled overall | |
| Any AE | 57.10 (54.66 – 59.52) | 49.78 (47.12 – 52.44) | 55.65 (53.14 – 58.15) | 49.92 (47. 16 – 52.69) | 63.02 (56.80 – 69.03) | 48.75 (41.02 – 56.51) | 5.26 (3.03 – 7.50) | 12.64 (7.29 – 17.99) | 6.73 (4.58 – 8.87) |
| Serious AE | 1.79 (1.59 – 2.00) | 1.42 (1.15 – 1.71) | 1.82 (1.59 – 2.06) | 1.29 (1.02 – 1.58) | 1.70 (1.30 – 2.14) | 1.87 (1.06 – 2.86) | 0.36 (0.06 – 0.67) | −0.09 (-1.0 – 0.84) | 0.28 (-0.01 – 0.58) |
| AE leading to discontinuation | 2.17 (1.67 – 2.71) | 1.90 (1.50 – 2.34) | 1.40 (1.11 – 1.70) | 1.49 (1.11 – 1.92) | 6.47 (4.08 – 9.33) | 3.61 (2.67 – 4.68) | 0.12 (-0.17 – 0.40) | 2.85 (0.53 – 5.17) | 0.22 (0.53 – 5.17) |
| Infectious AE | 20.27 (17.63 – 23.04) | 15.57 (13.61 – 17.64) | 20.09 (17.23 – 23.10) | 15.56 (13.46 – 17.78) | 21.51 (15.24 – 28.52) | 15.69 (10.28 – 21.94) | 4.31 (2.83 – 5.79) | 4.14 (1.50 – 6.78) | 4.34 (2.99 – 5.69) |
| Injection- or Infusion-related AE | NA | NA | 4.92 (3.39 – 6.69) | 1.69 (1.00 – 2.50) | NA | NA | 3.40 (1.91 – 4.89) | NA | NA |
Pooled proportion of patients experiencing adverse events and risk difference between systemic therapy and placebo stratified by treatment class.
AE, adverse event; CI, confidence interval; NA, not applicable.
Bolded values are significantly different from 0 testing at a significance level of 5%.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
psoriasis, systemic therapy, nocebo effect, randomized controlled trial, biologic
Citation
Ma B, Park Y-J, Barber K and Mydlarski PR (2024) Corrigendum: Nocebo effects in systemic therapies for adult plaque psoriasis: a systematic review and meta-analysis. Front. Med. 11:1439345. doi: 10.3389/fmed.2024.1439345
Received
27 May 2024
Accepted
18 June 2024
Published
27 June 2024
Volume
11 - 2024
Edited and reviewed by
Robert Gniadecki, University of Alberta, Canada
Updates
Copyright
© 2024 Ma, Park, Barber and Mydlarski.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: P. Régine Mydlarski rmydlars@ucalgary.ca
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.